Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR),
Role: Investigator,
CareDx, Inc.,
(10/2025 - 10/2026)
Status: Approved
A phase 3 prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transplants,
Role: Investigator,
Medeor Therapeutics, Inc.,
(05/2023 - 04/2024)
Status: Completed
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND),
Role: Investigator,
Biogen,
(04/2026 - 04/2027)
Status: Approved
Biogen MA Inc/ "A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE}" 299AR201,
Role: Investigator,
Biogen,
(03/2026 - 03/2027)
Status: Approved
Internal
Highly Suppressive Regulatory T Cell as a Biomarker for Immunologically Relevant Delayed/Slow Graft Function after Kidney Transplantation,
Role: Investigator,
LLU Dept. of Surgery,
(10/2020)
Status: Approved
Incidence of Glomerular Disease Post-Kidney Transplant,
Role: PI,
LLU Dept. of Medicine,
(10/2024)
Status: Approved
Assessment of IVIG in highly sensitized patients with panel reactive antigen (PRA) of over 94%.,
Role: Investigator,
LLU Transplantation Institute,
(04/2025)
Status: Approved
Transplantation of HCV positive donor kidneys in HCV negative or previously successfully treated recipients,
Role: Investigator,
LLU Transplantation Institute,
(11/2025 - 11/2026)
Status: Approved
Comparing Antithymocyte Globulin and Basiliximab Induction Therapy in Pancreas Transplant Patients: A Single-institution Retrospective Study,
Role: Investigator,
LLU Transplantation Institute,
(10/2025)
Status: Approved
Non-Profit Organization
Integration of donor-derived cell-free DNA with HLA-DR+TNFR2+ regulatory T cell in the prediction of acute rejection and graft function after kidney transplantation,
Role: Investigator,
American Society of Transplant Surgeons,
(08/2025 - 08/2026)
Status: Approved